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Abstract
Background: Neoantigens that arise as a consequence of tumor-specific mutations can be recognized by T lymphocytes
leading to effective immune surveillance. In colorectal cancer (CRC) and other tumor types, a high number of
neoantigens is associated with patient response to immune therapies. The molecular processes governing the
generation of neoantigens and their turnover in cancer cells are poorly understood. We exploited CRC as a
model system to understand how alterations in DNA repair pathways modulate neoantigen profiles over time.
Methods: We performed whole exome sequencing (WES) and RNA sequencing (RNAseq) in CRC cell lines, in
vitro and in vivo, and in CRC patient-derived xenografts (PDXs) to track longitudinally genomic profiles, clonal
evolution, mutational signatures, and predicted neoantigens.
Results: The majority of CRC models showed remarkably stable mutational and neoantigen profiles; however,
those carrying defects in DNA repair genes continuously diversified. Rapidly evolving and evolutionary stable
CRCs displayed characteristic genomic signatures and transcriptional profiles. Downregulation of molecules
implicated in antigen presentation occurred selectively in highly mutated and rapidly evolving CRC.
Conclusions: These results indicate that CRCs carrying alterations in DNA repair pathways display dynamic
neoantigen patterns that fluctuate over time. We define CRC subsets characterized by slow and fast evolvability and
link this phenotype to downregulation of antigen-presenting cellular mechanisms. Longitudinal monitoring of the
neoantigen landscape could be relevant in the context of precision medicine.
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Background
Anticancer therapies based on immune-checkpoint block-
ade are often remarkably effective but benefit only a minor
fraction of cancer patients [1]. Several biomarkers of
response and resistance to immune modulators have been
proposed [2, 3]. Among these, the overall mutational
burden (number of somatic variants per megabase (Mb))
and the number of predicted neoantigens were highlighted
in multiple studies [4–6]. The predictive values of muta-
tional and antigen burdens are still being evaluated in
clinical settings. Both parameters are presently assessed
on DNA extracted from individual tissue samples and are
typically measured only once in the clinical history of each
patient. Alterations in DNA repair pathways, including
mutations or promoter hypermethylation of mismatch
repair (MMR) effectors (MLH1, MSH2, etc.) or DNA
polymerases (polymerase ε and δ) [7], are known to
increase the mutational burden and the neoantigen
profiles of cancers [8]. Whether, and to what extent,
neoantigen profiles evolve over time as a result of the
inherent genomic instability of individual tumors is largely
unknown. We recently reported that in mouse models,
inactivation of DNA mismatch repair increases the muta-
tional burden and leads to dynamic mutational profiles
resulting in effective cancer immune response [9]. Here
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we exploit CRCs as a model system to understand
whether mutational burden and neoantigen profile of
human tumors evolve over time as a result of their dis-
tinctive genomic landscapes.
Methods
CRC cell lines
The source of each cell line is reported in Table 1. All
cell lines were maintained in their original culturing
conditions according to supplier guidelines. Cells were
ordinarily supplemented with FBS 10%, 2 mM L-glutam-
ine, and antibiotics (100 U/mL penicillin and 100 mg/mL
streptomycin) and grown in a 37 °C and 5% CO2 air
incubator. To study the evolution of cell populations,
cell lines were not cloned prior to the experiment or at
any subsequent time point. Cell lines were thawed in a
10-cm dish. After thaw recovery, each cell line was
screened for the absence of mycoplasma contamination
and checked for its identity, referred below as quality
control (QC). To preserve heterogeneity, upon thawing,
individual lines were expanded to at least 108 cells. At
this point for each model, cells were counted, and the
percentage of alive/dead cells was calculated. At the
beginning of the experiment (T0), 4 × 107 live cells were
distributed as follows: (A) 2 × 106 cells were re-plated in
a 10-cm dish for in vitro propagation, (B) 3 × 107 cells
were used for in vivo experiments, (C) 2 × 106 cells were
frozen, and (D) 3 pellets (2 × 106 cells each) were frozen
for DNA, RNA, and protein extraction. Cells plated as
in (A) were kept in culture changing medium twice a
week and dividing them at a constant splitting rate,
determined before initiating the experiment. In details,
splitting was performed before full confluency was
achieved. The number of cells that were split and the
number of passages and days of culture were recorded
for each cell model to calculate the doubling time.
During in vitro culture, cell populations were collected at
the following pre-determined time points: 30 days (T30),
60 days (T60) and 90 days (T90) from T0. At each time
point, a fraction of the cells were put aside (note that this
did not affect the rate of passaging described below) and
pellets (2 × 106 each) were collected for DNA, RNA, and
protein extraction. QC was repeated at each time point.
Cell quality control (QC)
Cells were screened for the absence of mycoplasma con-
tamination using the Venor®GeM Classic kit (Minerva
Biolabs). The identity of each cell line was checked be-
fore starting each experiment and after every genomic
DNA extraction by PowerPlex® 16 HS System (Promega),
through Short Tandem Repeats (STR) at 16 different loci
(D5S818, D13S317, D7S820, D16S539, D21S11, vWA,
TH01, TPOX, CSF1PO, D18S51, D3S1358, D8S1179,
FGA, Penta D, Penta E, and amelogenin). Amplicons
from multiplex PCRs were separated by capillary elec-
trophoresis (3730 DNA Analyzer, Applied Biosystems)
and analyzed using GeneMapper v 3.7 software (Life
Technologies).
Microsatellite instability (MSI) status
The MSI status was assessed with the MSI Analysis
System kit (Promega). The analysis requires a multiplex
amplification of seven markers including five mononucle-
otide repeat markers (BAT-25, BAT-26, NR-21, NR-24,
and MONO-27) and two pentanucleotide repeat markers
(Penta C and Penta D). The products were analyzed by
capillary electrophoresis in a single injection (3730 DNA
Analyzer, ABI capillary electrophoresis system (Applied
Biosystems). Then, the results were analyzed using
GeneMapper V5.0 software.
DNA extraction and exome sequencing
Genomic DNA (gDNA) was extracted from CRC cell lines,
xenografts, and PDXs using Maxwell® RSC Blood DNA kit
(AS1400, Promega). DNA was sent to IntegraGen SA (Evry,
France) that performed library preparation, exome capture,
sequencing, and data demultiplexing. Final DNA libraries
were pair-end sequenced on Illumina HiSeq4000 as paired-
end 100 bp reads.
Mutational analysis in cell lines
When cell lines were passaged in mice or when analyz-
ing patient-derived xenografts, Fastq files were first
processed with Xenome [10] to remove reads of mouse
origin. Reads files were aligned to the human reference
hg38 using BWA-mem algorithm [11], and then the
“rmdup” samtools command was used to remove PCR
duplicates [12]. On the resulting aligned files, we ob-
served a median depth of 138x with 98% of the targeted
region covered by at least one read. Bioinformatic mod-
ules previously developed [9, 13] by our laboratory were
used to identify single nucleotide variants (SNVs) and
indels. The mutational characterization of the 64 cell
lines at time point 0 was assessed by calling the alter-
ations against the hg38 reference annotation. Then, a
series of filters were used to remove germline variants
and artifacts: alleles supported by only reads with the
same strand, excluding start and end read positions from
the count, were discarded; variants called with allelic fre-
quency lower than 10% as well a p value greater than
0.05 (binomial test calculated on allele count and depth
of each sample) were excluded; common dbSNP version
147 and a panel of normal (40 samples) from previous
sequencing were used to annotate and filter germline
variants and sequencing artifacts. The variant calls of 45
cell lines at time point 90 and the 18 cell lines explanted
from mice were performed using the allele comparison
strategy between the same cell line at time 0 and time
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Table 1 Molecular, functional characteristics and source of origin of the indicated cell lines
Sample Microsatellite
status
Altered MSI markers Genome
evolvability
Split
ratio
In vitro
doubling time
Growth rate Source
C10 Stable – Stable 0.34 2.33 0.30 ECACC
C106 Stable – Stable 0.35 2.50 0.28 ECACC
C125PM Stable – Stable 0.34 2.37 0.29 ECACC
C32 Stable – Stable 0.18 1.54 0.45 ECACC
C70 Stable – Stable 0.4 2.76 0.25 ECACC
C75 Stable – Stable 0.36 2.46 0.28 ECACC
C99 Stable – NA NA NA NA ECACC
CACO2 Stable – Stable 0.26 1.83 0.38 ATCC
CAR1 Stable – Stable 0.36 2.47 0.28 JCRB
CCK81 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.34 2.53 0.27 RIKEN
CL14 Stable – NA NA NA NA DSMZ
COCM1 Stable – Evolving 0.3 2.34 0.30 JCRB
COGA1 Unstable bat26-mono27-nr24 NA NA NA NA Dr. Hubera
COGA2 Stable – Stable 0.32 2.22 0.31 Dr. Hubera
COGA5 Stable – Stable 0.20 1.69 0.41 Dr. Hubera
COGA8 Stable – Stable 0.22 1.67 0.41 Dr. Hubera
COLO201 Stable – NA NA NA NA ATCC
COLO94H Stable – Stable 0.45 2.81 0.25 CLS
DIFI Stable – NA NA NA NA Dr. Baselgab
DLD1 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.07 0.98 0.71 NCI60
HCA24 Stable – Evolving 0.33 2.22 0.31 ECACC
HCA46 Stable – Stable 0.4 2.41 0.29 ECACC
HCC2998 Stable – Stable 0.34 2.33 0.30 NCI60
HDC114 Stable – Evolving 0.23 1.69 0.41 DKFZc
HDC142 Stable – Evolving 0.35 2.42 0.29 DKFZc
HDC82 Stable – NA NA NA NA DKFZc
HRA16 Stable – NA NA NA NA ECACC
HROC24 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.16 1.23 0.56 Dr. Linnebacherd
HROC32 Stable – Stable 0.62 6.07 0.11 Dr. Linnebacherd
HROC334 Stable – Stable 0.45 2.83 0.24 Dr. Linnebacherd
HROC39 Stable – Stable 0.5 3.92 0.18 Dr. Linnebacherd
HROC69 Stable – Stable 0.33 2.26 0.31 Dr. Linnebacherd
HT115 Stable – Evolving 0.24 1.78 0.39 ECACC
HT29 Stable – Stable 0.16 1.38 0.50 NCI60
HT55 Stable – Stable 0.33 2.21 0.31 ECACC
LIM1215 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.15 1.24 0.56 Dr. Whiteheade
LIM2099 Stable – Stable 0.33 2.26 0.31 Dr. Whiteheade
LOVO Unstable nr21-bat25-mono27-nr24 NA NA NA NA ATCC
LS180 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.25 1.90 0.37 ATCC
LS411N Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.32 2.29 0.30 ATCC
MDST8 Stable – Stable 0.15 1.31 0.53 ECACC
NCIH716 Stable – NA NA NA NA ATCC
OUMS23 Stable – Stable 0.26 1.70 0.41 JCRB
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point 90 and xenograft respectively. Only variants present
at time point 90 (or in xenograft) were kept. Artifact
removal was employed as described above. To calculate
the tumor mutational burden (number of variants/Mb),
only coding variants were considered. Those variants were
used to predict neoantigens using previously published
methods [9, 14]. Briefly, RNAseq data were used as input
of “OptitypePipeline” [15] to assess the HLA status of
each sample at time point 0, then NetMHC 4.0 software
[16] was employed to analyze mutated peptides derived
from variant calls using kmer of 8–11 length. Next, for
each SNV, we modified the corresponding cDNA in the
selected position and we examined the 5′ and 3′ context.
The latter was set taking into account the length (in terms
of amino acids) with which the putative antigen could
bind HLA. We translated the cDNA and feed mutant
peptide to NetMHC with the proper HLA(s). For frame-
shifts, we applied the same approach considering every
possible peptide generated by the new frame. Finally,
RNAseq data were used to annotate and then filter
according to expression values (fragments per kilobase
million (FPKM) > 10). Only predicted neoantigens with a
strong binding affinity (Rank < 0.5) were considered for
further analysis.
Mutational analysis of patient-derived xenograft
WES of patient-derived xenografts was performed at
IntegraGen SA (Evry, France). Sequenced samples in-
cluded a microsatellite stable (MSS), a microsatellite
unstable (MSI), and a POLE mutant case (5, 7, and 6
respectively). Samples were analyzed with the same
bioinformatic pipeline applied to cell lines, and murine
reads were first removed using Xenome [10]. A median
depth of 130x and with 98% of the targeted region
covered by at least one read was observed. All 18 PDX
samples were characterized by calling alterations against
the hg38 reference annotation. For each generation, with
the exception of the first one, the mutational evolution
was inferred by subtracting the mutations of the previous
generation. Second-generation samples were compared to
Table 1 Molecular, functional characteristics and source of origin of the indicated cell lines (Continued)
Sample Microsatellite
status
Altered MSI markers Genome
evolvability
Split
ratio
In vitro
doubling time
Growth rate Source
OXCO3 Stable – Stable 0.23 1.76 0.39 Dr. Cerundolof
RW7213 Stable – Stable 0.4 2.60 0.27 Dr. Arangog
SNU1040 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.54 4.14 0.17 KCLB
SNU1181 Stable – Stable 0.62 4.65 0.15 KCLB
SNU1235 Stable – Evolving 0.35 2.33 0.30 KCLB
SNU1411 Stable – Evolving 0.44 2.76 0.25 KCLB
SNU1460 Stable – NA NA NA NA KCLB
SNU1684 Unstable bat26-nr21-bat25-mono27-nr24 NA NA NA NA KCLB
SNU175 Unstable bat26-nr21-bat25-mono27 NA NA NA NA KCLB
SNU283 Stable – NA NA NA NA KCLB
SNU479 Stable – NA NA NA NA KCLB
SNU81 Stable – Evolving 0.42 2.33 0.30 KCLB
SNU977 Stable – Stable 0.42 2.71 0.26 KCLB
SNUC1 Stable – NA NA NA NA KCLB
SW1417 Stable – NA NA NA NA ATCC
SW1463 Stable – NA NA NA NA ATCC
SW480 Stable – Stable 0.18 1.64 0.42 ATCC
SW837 Stable – Stable 0.27 2.07 0.34 ATCC
V411 Stable – Stable 0.22 1.91 0.36 Dr. Markovitzh
V481 Unstable bat26-nr21-bat25-mono27-nr24 NA NA NA NA Dr. Markovitzh
WIDR Stable – NA NA NA NA Dr. Bernardsi
Non-commercial cell lines were provided by (a) Dr. L. A. Huber, Cell Biology/Biocenter, Medical University of Innsbruck, Innsbruck, Austria; (b) Dr. Baselga,
Chairman & Professor of Medicine, Vall d’Hebron Institute of Oncology (V.H.I.O.), Vall d’ Hebron University Hospital, Barcelona, Spain; (c) Dr. M. Schawb, Division of
Tumour Genetics - B030 German Cancer Research Center (DKFZ), Heidelberg, Germany; (d) Dr. M. Linnebacher, Division of Molecular Oncology and
Immunotherapy, Department of General Surgery, University of Rostock, Rostock, Germany; (e) Dr. R.H. Whitehead, Depts of Medicine, Cell and Developmental
Biology and Cancer Biology, Vanderbilt University, Nashville, USA; (f) Dr. V. Cerundolo, Nuffield Dept of Clinical Medicine, John Radcliffe Hospital, Oxford, UK; (g)
Dr. D. Arango, Group of Molecular Oncology, Nanomedicine Research Program, Molecular Biology and Biochemistry Research Center, CIBBIM Nanomedicine, Vall
d’Hebron, Barcelona, Spain; (h) Dr. S. Markovitz, Case Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, Case Western
Reserve University, Cleveland, USA; (i) Dr. R. Bernards, Division of Molecular Carcinogenesis B7, Netherlands Cancer Institute, Amsterdam, The Netherlands.
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the first-generation samples, samples from the third ge-
neration were compared to the 2nd generation samples,
and so on.
Ploidy estimation
Gene copy-number (GCN) was calculated in a two-step
approach: initially, we treated cell lines as diploid and
considered the median read depth of all coding regions
as the level for 2N ploidy. We also calculated the median
read depth for every gene. The ratio between the two
median values was then considered as the relative GCN.
In the second step, to estimate the overall ploidy, we
segmented all chromosomes using a custom script that
implements circular binary segmentation. Finally, we
exploited the distribution of allelic frequencies for indi-
vidual segments to assess the absolute GCN. This was
necessary since distinct ploidy levels have different ex-
pected distributions. For example, a 2N ploidy status has
a bell-shaped curve with a peak of 50% and a 3N ploidy
is expected to have two peaks on 33% and 66%.
Mutational signature
Mutational signatures were calculated using the web
application “Mutational Signatures in Cancer” (MuSiCa)
[17]. The profile of each signature is calculated using the
six substitution subtypes: C>A, C>G, C>T, T>A, T>C,
and T>G (all substitutions are referred to by the pyri-
midine of the mutated Watson–Crick base pair). In-
formation on nucleotides 5′ and 3′ to each mutated
base are incorporated to generate 96 possible mutation
types. For each sample, a tab-separated value file was
created with chromosome, position, reference, and
alternate alleles. Only samples with at least 10 mutations
were included. The output file of MuSiCa that includes
the contribution values of 30 signatures [18] was used
to create a clustermap with seaborn, a Python data
visualization library, setting Euclidean metric and the
average linkage method.
Doubling time
Cell lines were passaged in vitro for a minimum of 85 to a
maximum of 103 days. Each passage was performed before
full confluency was achieved, and the total number of
doublings was annotated for each cell model. Two para-
meters, number of passages (n) and days of culture (t), were
used to estimate the growth rate (GR) and the doubling
time (DT) assuming that every division is an independent
random event; probability distribution of division is equal
for all cells and it is an exponential distribution; and the
number of cells in each plate before confluence is fixed (K).
The growth rate is defined as GR = logn (2) ÷ DT [19].
The estimated number of cells at time t is defined as
N(t) = N(0) × e(GR × t) where N(0) is the number of cells
at time 0. Therefore, GR = logn(N(t) ÷ N(0)) ÷ t where
N(t) ÷ N(0) = (K × 2n) ÷ (K × 20) = 2n and so GR =
logn(2
n) ÷ t. Finally, DT = t × logn (2) ÷ logn(2
n).
RNA extraction and RNAseq analysis
Total RNA was extracted from a pellet of CRC cells (2 ×
106 cells) using Maxwell® RSC miRNA Tissue Kit (AS1460,
Promega), according to the manufacturer’s protocol. The
quantification of RNA was performed by Thermo Scientific
Nanodrop 1000 (Agilent) and Qubit 3.0 Fluorometer (Life
Technologies). RNA integrity was evaluated with the
Agilent 2100 Bioanalyzer using the Agilent RNA 6000
Nano Kit. Total RNA (800 ng) with RNA integrity number
(RIN) score between 9 and 10 was used as input to the
Illumina TruSeq RNA Sample Prep Kit v2-Set B (48Rxn),
according to the manufacturer’s protocol. The standard
RNA fragmentation profile was used (94 °C for 8min for
the TruSeq RNA Sample Prep Kit). PCR-amplified RNA-
seq library quality was assessed using the Agilent DNA
1000 kit on the Agilent 2100 BioAnalyzer and quantified
using Qubit 3.0 Fluorometer (Life Technologies). Libraries
were diluted to 10 nM using Tris-HCl (10mM pH 8.5) and
then pooled together. Diluted pools were denatured ac-
cording to the standard Illumina protocol, and 1.8 pM were
run on NextSeq500 using high output Reagent cartridge V2
for 150 cycles. A single-read 150-cycle run was performed.
FastQ files produced by Illumina NextSeq500 were aligned
using MapSplice2 [20] transcriptome-aware aligner using
hg38 assembly as reference genome. The resulting BAM
files were post-processed to translate genomic coordinates
to transcriptomic ones and to filter out alignments carrying
insertions or deletions (which RSEM does not support) or
falling outside the transcriptome regions. The post-
processed BAM alignment was given as input to RSEM
[21] for gene expression quantification using GENCODE
v22 as gene annotation.
Differential expression analysis
The abundance quantification generated with RSEM pro-
vides the FPKM and the expected counts for each gene.
The latter was used to perform genes differential ex-
pression analysis with DESeq2 R package (library Bio-
conductor) [22] given two distinct groups of interest, one
of which considered as the reference. Genes were consi-
dered as differentially expressed if the adjusted p value
was less than 0.05, and the log2 fold change was less or
equal to −1 (if median FPKM value of the reference group
was greater or equal to 10), or the log2 fold change was
greater or equal to 1 (if median FPKM of the target group
was greater or equal to 10). The analyses were performed
between the following groups: MSI vs MSS (reference),
hypermutated vs non-hypermutated (reference), and
“EVOLVING-CRC” vs “STABLE-CRC” (reference). The
hypermutated group included MSI and MSS POLE-
mutated cell lines (18 samples). EVOLVING-CRC group
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included all samples with at least 10 alterations acquired
per day. A multi-factor configuration of the expression
analysis was designed including extra variables of interest
such as growth rates or the number of mutations normal-
ized to doubling time.
Pathway analysis
Genes differentially expressed were then analyzed with
g:Profiler [23], an online pathway analysis tool that takes
a list of genes and assigns them to different families of
biological functions. We set the query options to select
significant biological processes only, and we retained
(for further analysis) only the topmost families of the
hierarchy (depth 1).
Xenograft mouse model
Each CRC cell line (5 × 106 cells) was injected subcuta-
neously into both flanks of two 6-week-old female NOD
(nonobese diabetic)/SCID (severe combined immunode-
ficient) mice (Charles River Laboratory). Tumor size was
measured twice a week and calculated using the formula:
V = ((d)2 × (D)) ÷ 2 (d =minor tumor axis; D =major
tumor axis). Tumors were explanted when they reached
a volume of 1000 mm3. The investigators were not
blinded, and measurements were acquired before the
identification of the cages.
Patient-derived mouse model
Tissue from hepatic metastasectomy of CRC patients
was collected at surgery and implanted in NOD-SCID
a
b
c d
Fig. 1 Analysis of mutational burden in a panel of 64 CRC cell lines. Mutational characterization and comparison of SNVs and frameshifts among
MSS (46 samples), MSI (12 samples), and POLE mutated (6 samples) of CRC models. a The distribution of SNVs per Mb of coding DNA at time 0 is
shown for each cell line. b The number of frameshift mutations at time 0 is shown for each cell line. c The number of SNVs per each group is
shown (“MSS” refers to MSS cells without POLE mutations; “MSI” includes MSI cells, as well as the SNU1040 cell line which is both MSI and POLE
mutated; “POLE” includes only MSS cell lines carrying a POLE mutation). d The number of frameshifts per group is shown. The center line of each
box plot indicates the median. p < 0.0001
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mice as described previously [24]. When reaching a vol-
ume of 1500–2000mm3, the tumors were explanted,
fragmented, and serially passaged in new mice. At each
passage, part of the material was frozen for molecular
analyses. Samples’ genetic identity was determined by
Sequenom-based analysis of 24 highly variable SNPs of
germline DNA (Table 2), confirmed by analyzing pre-
implantation tumor material, and then validated every
second passage in mice. The study population consisted
of matched tumor and normal samples from 3 CRC
patients that underwent surgical resection of liver
metastases at the Candiolo Cancer Institute (Candiolo,
Torino, Italy) and at the Mauriziano Umberto I Hospital
(Torino) between 2009 and 2013. Patients signed
informed consent, and the study was approved by the
relevant institutional Ethics Committees.
Western blotting analysis
Proteins were extracted by solubilizing the cells in boiling
SDS buffer (50mM Tris-HCl [pH 7.5], 150mM NaCl, and
1% SDS). Samples were boiled for 5min at 95 °C and soni-
cated for 10 s. Extracts were clarified by centrifugation,
normalized with the BCA Protein Assay Reagent kit
(Thermo). Equal amounts of proteins (20 μg) were loaded
in each lane. Proteins were separated by PAGE and trans-
ferred to nitrocellulose sheets. Western blot detection was
performed with enhanced chemiluminescence system
(GE Healthcare) and peroxidase-conjugated secondary
antibodies (Amersham). The following primary anti-
bodies were used for western blotting: anti-beta2
Microglobulin [EP2978Y] (ab75853, Abcam), anti-MLH1
(ab92312, Abcam), anti-MSH2 (ab70270, Abcam),
anti-MSH6 [EPR3945] (ab92471, Abcam), anti-MSH3
PA527864, Invitrogen, anti-PMS2 EPR3947 (Cell Marque
Corporation, USA), anti-actin (I-19) (sc1616, Santa Cruz),
and anti-HSP 90α/β (H-114, sc-7947, Santa Cruz).
Images were acquired with Chemidoc (Biorad), and
western blot band intensity was analyzed using Image
Lab software (Biorad).
Results
We selected from our database 64 CRC cell lines designed
to recapitulate clinically relevant characteristics of CRC
patients (Table 1 and Additional file 1: Figure S1a). Whole
exome sequencing and RNAseq were performed on all
models. Using previously developed computational tools
Table 2 List of SNPs used to identify patient-derived xenografts
Probe SNP GENE Chr Functional consequence
AMG_mid100
rs11017876 [A\G] DOCK1 10:127402700 Intron variant
rs1106334 [C\T] 8:70100576
rs1155741 [C\T] ITGA9 3:37585621 Intron variant
rs11655512 [A\G] LOC339260 17:20948422 Intron variant
rs11940551 [G\T] 4:27160856
rs1210110 [A\G] PRDM2 1:13770326 Intron variant
rs1364054 [C\T] LINC00299 2:8038605 Intron variant
rs1528601 [C\G] 16:51064516
rs161792 [A\T] LOC101928166 3:152181915 Intron variant
rs17272796 [C\T] PLCL2 3:17035776 Intron variant
rs242076 [C\T] SYN3 - TIMP3 22:32833844 Intron variant
rs4775699 [C\T] SEMA6D 15:47581352 Intron variant
rs4793172 [A\T] DCAKD 17:45054112 Intron variant
rs4905366 [A\G] 14:95636762
rs6603251 [C\T] PPP2R3B Y:359845 Intron variant
rs6734275 [A\G] LOC105374785 2:67014042 Intron variant
rs685449 [A\T] RGS17 6:153023396 Intron variant
rs7555566 [A\G] KAZN 1:14478378 Intron variant
rs7584993 [A\C] 2:222981224
rs7808249 [A\G] CROT 7:87354399 Intron variant
rs9293511 [C\T] LOC105379072 5:89120537 Intron variant
rs9352613 [A\G] 6:78714716
rs9572094 [C\T] LOC105370159 13:34678745 Intron variant
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and bioinformatic algorithms [13, 14, 25, 26], we mea-
sured mutational burden (alterations per Mb) assessing
both SNVs and frameshifts (Fig. 1a, b, Additional file 2).
Scrutiny of genomic alterations highlighted that MSI cell
lines and those carrying known POLE hotspot mutations
had higher number of mutations per Mb as compared
to MSS cell lines (Fig. 1a). The type of DNA repair
alterations occurring in each model affected the
nature of mutations: MSI cells displayed a higher
number of frameshifts and indels than POLE mutant
cell lines; the opposite was true for SNVs (Fig. 1c, d).
Alterations in MMR and POLE genes are listed in Table 3
and Additional file 1: Figure S1b. The cell line with the
highest number of variants (SNU1040) carried inactivating
alterations in both MLH1 and POLE (Additional file 1:
Figure S1b). Altogether, these results are consistent with
what has been reported in CRC patients carrying alterations
in the MMR DNA repair pathway, indicating that the
cell models included in this study broadly recapitulate
what is observed in clinical specimens [27].
To assess whether, and to what extent the basal
mutational profiles (Time 0: T0) evolved over time,
we passaged 45 cell lines for 90 days and collected a
second set of samples (Time 90: T90) (Additional file 1:
Figure S2). These were subjected to WES and analyzed
using the computational pipeline described above. Across
all cell lines globally, the total mutational burden was
similar between T0 and T90 (Additional file 1: Figure S3).
However, when the T0 and T90 mutational profiles were
compared, prominent differences were detected among
models sharing specific DNA repair defects (Fig. 2a).
Specifically, the mutational landscapes of most MSI and
POLE mutant cells evolved very rapidly through the gen-
eration of novel SNVs and frameshifts (Fig. 2a). On the
contrary, the majority of MSS models showed more stable
profiles (Fig. 2a). We sought to minimize confounding ef-
fects due to differences in cell-intrinsic doubling times
(Table 1); we therefore calculated the doubling time of all
cell models (Table 1, Additional file 1: Figure S4). Notably,
evolvability trends remained apparent after normalization
for doubling time (Additional file 1: Figure S5). We desig-
nated rapidly evolving CRC cells as EVOLVING-CRC and
evolutionary stable CRC cell as STABLE-CRC (Table 1).
We empirically define EVOLVING-CRCs as those cells
that acquire 10 alterations (or more) per day after
normalizing mutation data to the doubling time of cell
lines (Table 1). Moreover, EVOLVING-CRCs often
carried alterations in multiple genes involved in distinct
DNA repair functions, suggesting that defects in several
DNA damage response pathways might be co-selected
(Additional file 1: Figure S1b). The expression of
MMR genes was assessed by western blot at T0 and
a
b
Fig. 2 In vitro evolution of mutational landscape in 45 CRC cell lines. Mutational characterization of CRC cells after 90 days of culture (T90) in
vitro. a Bar charts show the number of novel alterations (SNVs and frameshifts) acquired at T90 (not present at T0) for each cell line. b The
number of predicted neoantigens (see the “Methods” section) is shown. Each bar represents putative neoepitopes derived from SNVs
and frameshifts
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T90, and no differences were observed (Additional file 1:
Figure S6).
The genome of four CRC lines classified as MSS
(SNU1235, COCM1, HDC142, and SNU1411) exhibited
dynamic mutational profiles (Fig. 2). In an attempt to
decipher the molecular basis of these findings, whole
exome data of the outliers were carefully examined,
focusing on genes previously implicated in DNA repair
pathways that are not routinely subjected to scrutiny in
CRC patients. We found that SNU1235 and HDC142
models carried biallelic alterations in the EXO1 (S510*)
and MUTYH (S179C) genes, respectively. The exonucle-
ase EXO1 is implicated in both MMR (it binds MLH1)
and base excision repair [28], while MUTYH encodes a
DNA glycosylase that is involved in oxidative DNA
damage repair and is part of the base excision repair
pathway [29]. Germline mutations in MUTYH cause
MUTYH-associated polyposis (MAP) [30]. Scrutiny of
the COCM1 exome revealed a POLE variant (A629D).
A629 is localized in a region of POLE highly conserved
during evolution (Additional file 1: Figure S7). The
A629D change is potentially damaging according to the
SIFT [31] and Polyphen [32] algorithms, which predict
the putative impact of amino acid substitutions on
human proteins using structural and comparative evolu-
tionary considerations.
We next addressed how longitudinal evolution of CRC
cell genomes affected their predicted neoantigen profile.
To this end, WES, RNAseq, and HLA prediction data were
combined as previously described [9]. In detail, we iden-
tified genomic variants that satisfied three criteria: (i)
emerged over time, (ii) occurred in transcribed genes, and
(iii) scored positively when HLA I matching algorithms
were applied. The variants that emerged after deploying
the above computational pipeline were classified as puta-
tive neoantigens (Fig. 2b). Hypermutated and EVOLVING-
CRC cells displayed higher levels of putative neoantigens
compared to slowly evolving CRC cells (Fig. 2b). Moreover,
and consistent with their predicted effects on antigenicity,
a high prevalence of indels and associated frameshifts,
Fig. 3 Lost and gained mutations across evolving CRC cell lines. For each CRC model, the allelic frequency of SNVs at T0 and T90 are shown.
Mutations were called against the reference genome (hg38) with allelic frequency > 1. The y-axis reports all the mutations found in each cell line,
whereas the time points data are reported on x-axis
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which occur in MSI CRCs, translated into higher numbers
of predicted neoantigens in this subset (Fig. 2b).
Next, we studied whether in parallel to mutation
gains we could also detect loss of variants over time.
For this reason, we tracked lost and gained alteration in
“evolving” cell lines over time. As expected, variants
that did not change over time showed high allelic
frequency, likely reflecting their clonal (trunk) status.
Mutations that emerged or were lost showed lower
allelic frequency (Fig. 3).
Mutational signatures are characteristic combina-
tions of mutation types arising from mutagenesis
processes such as alterations in DNA replication, ex-
posure to DNA damaging agents, tissue culture con-
ditions, and DNA enzymatic editing [18]. In human
tumors, over 30 mutational signatures have been
identified, a subset of which are linked to defective
DNA repair pathways. For example, signatures 6, 15,
20, and 26 are associated with MMR defects and signa-
ture 10 is linked to inactivating mutation in the
proofreading domain of DNA polymerases, while signa-
ture 18 appears to explain the rise of 8-oxoG:A mis-
matches due to MUTYH biallelic alteration [33].
We reasoned that the remarkable evolvability observed
in a subset of CRC cells might be reflected in their
mutational signatures. To test this, we first identified
mutational signatures at T0. As expected, MSI cells
displayed signatures 6, 15, 20, and 26, while POLE
mutant cells showed primarily mutational signature 10
(Additional file 1: Figure S8).
We next assessed which signatures were acquired
(remained active) during replication of the cells in
vitro by comparing samples collected at T0 and T90.
We found that in most instances, DNA alterations
linked to MMR and POLE defects continued to
occur over time, indicating that the corresponding
DNA repair capabilities were permanently disabled
(Fig. 4a).
Replication of cancer cell populations in 2D is thought
to encounter little or no selective pressure as the cells are
a b
Fig. 4 Mutational signatures associated with alterations emerging during in vitro or in vivo CRC propagation. Analysis of 30 validated cancer-
associated mutational signatures in hypermutated/rapidly evolving CRC cell lines. Signatures associated to MMR-deficient (6, 15, 20, 26), POLE-
dependent (10), and MUTYH-associated polyposis (18) are highlighted. Analysis and clustering were performed as reported in the “Methods”
section. a Heatmap of signature contributions during replication of CRC cells in vitro by analyzing alterations acquired at T90. b Heatmap of
signature contributions during replication of the CRC cells in vivo by comparing xenograft tumors to the corresponding cells at T0 (see the
“Methods” section for detailed information)
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cultured in the same conditions for many generations be-
fore the experiment is started. To monitor mutational and
neoantigen evolution under more stressful (selective) con-
ditions, CRC cells including MSS, MSI, and POLE models
were transplanted in immunodeficient (NOD SCID) mice
and allowed to grow until they reached approximately
1000 mm3 in size, after which tumors were excised. Al-
though NOD SCID mice have no adaptive immunity, the
mouse stromal microenvironment and elements of cellu-
lar innate immunity are known to affect the growth of hu-
man cancer cells in vivo [34]. DNA samples were obtained
before implantation and at the end of the experiment.
WES was performed, and the data were analyzed with the
same bioinformatic pipeline applied to cells grown in vitro.
The mutational profiles revealed higher evolutionary rates
in vivo than in vitro (Additional file 1: Figure S9a, b). This
translated into increased levels of predicted neoantigens in
vivo (Additional file 1: Figure S9c). Notably, mutational sig-
natures linked to MSI status and POLE mutations were
more marked in vivo than in vitro (Fig. 4b, Additional
file 1: Figure S10). We then assessed whether the
mouse microenvironment exerts selection on the cells ex-
panded in vivo and compared the results to cells passaged
in vitro. To this end, we characterized the ratio between
non-synonymous and synonymous mutations in vitro and
in vivo. We detected very limited or no selection in cells
passaged in vitro (ratio 3:1). Instead, in vivo the ratios for
lost and gained mutations were 1:1 and 2:1, respectively, in-
dicating a purifying selection (Additional file 1: Figure S11).
These findings suggest that when cells are transplanted in
mice they are subjected to environmental selection.
Next, we asked whether the evolutionary trajectories
observed in CRC cells with alterations in DNA repair
pathways also occurred in human CRC with analogous
molecular profiles. To this end, we selected MMR-
proficient, MMR-deficient, and POLE mutant cases
(Table 4) from our extensive patient-derived CRC xeno-
graft biobank [35]. Each model was serially transplanted
for at least four generations in immunodeficient mice as
described in the phylogenetic tree (Fig. 5a). Samples
collected at each transplantation were subjected to WES.
In some instances, simultaneous transplantation of the
Table 3 POLE mutations in CRC cells
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same tumor in two animals allowed acquisition of in-
dependent measurements for each generation. NGS data
were analyzed with the bioinformatic pipeline applied to
cells grown in vitro. These experiments revealed remark-
able differences in the evolvability of MSS, MSI, and POLE
CRC models in vivo and indicated that these charac-
teristics also occurred in patient-derived CRC samples
(Fig. 5b, c). As expected, high-frequency (clonal-trunk)
variants were conserved across generations. Interestingly,
the in vivo results differ from those obtained in cell
models in vitro. We find that in PDX models, not only
sub-clonal but also clonal populations can emerge in the
subsequent generation of colorectal cancers with DNA
repair defects (Fig. 6).
Furthermore, in MSI and POLE patient-derived xeno-
grafts, the mutational signatures were continuously (re)
generated and could be clearly recognized (Additional
file 1: Figures S12 and S13). In non-mutator (slow
evolving) cell lines, very few mutations emerged over
time, and thus, the possibility to assess mutational signa-
tures was limited. Because of this, in the slowly evolving
models, we were unable to reliably generate mutational
signatures.
Distinct subsets of CRCs can be recognized based on
histological characteristics, as well as their genomic,
epigenetic, and transcriptional profiles. As a result, CRC
can be classified into specific subsets, which are often
correlated with divergent clinical outcomes [36, 37]. The
rate of genomic evolution and the dynamics of neoantigen
profile have not yet been systematically explored as a
method to classify CRC. We therefore asked whether any
molecular traits (beyond alterations in DNA repair genes)
could distinguish EVOLVING-CRC and STABLE-CRC.
To address this question, we performed unbiased gene
copy number and transcriptional comparative analyses of
CRC cell lines. As previously reported, MSI CRC cells
a
b
c
Fig. 5 Genomic evolution in patient-derived xenografts. Phylogeny of the indicated patient-derived xenograft and their molecular characterization. a
MSS, MSI, and POLE mutant samples were serially transplanted for at least four generations (F1–F4) in NOD/SCID mice as shown. Samples collected at
each passage were subjected to WES. b WES data of each generation were compared with those obtained from the previous generation. Bar graphs
show de novo acquired SNVs and frameshifts at each generation. c The number of predicted neoantigens in each PDX is shown. Each bar represents
putative neoepitopes derived from SNVs and frameshifts (see the “Methods” section for detailed information)
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typically carried a close to diploid chromosomal status,
while MSS showed elevated aneuploidy (Fig. 7) [38].
Interestingly, the most rapidly evolving POLE mutant
lines, SNU81 and HDC114, also displayed a diploid
prevalent phenotype. Nonetheless, copy number and
ploidy status could not distinguish “EVOLVING” and
“STABLE” CRC models.
Next, we performed RNAseq on the entire dataset to
explore whether transcriptional profiles could classify
rapidly evolving CRC lines. Differential analysis of RNA-
seq data was initially performed comparing the MSS and
MSI sample groups. The list of differentially expressed
genes was consistent to results previously reported in
this setting, and 168 genes were differentially expressed
between these two groups (Table 5) [39]. Next, we eva-
luated genes differentially expressed in hypermutated ver-
sus non-hypermutated cells, grouping together MSI- and
POLE-mutated cell lines and comparing them to the MSS
lines (Fig. 8a). Notably, proteins associated with immune
response and predominantly with antigen-presenting and
antigen recognition functions were consistently
downregulated in cell lines with high mutational burden
(Fig. 8b). Next, we compared EVOLVING and STABLE
CRC models. The number of genes differentially expressed
with significant p value was smaller due to the reduced
number of available samples (Fig. 9a). Beta-2 microglobulin
(B2M) was downregulated in most EVOLVING as com-
pared to STABLE CRCs (Fig. 9b, c). Downregulation of
B2M was confirmed at the protein level (Fig. 9c) and was
frequently associated with premature stop codons in the
B2M gene (Fig. 9d). Interestingly, the four MSS models
(COCM1, SNU1235, SNU1411, and HDC142) with low
mutational burden but dynamic mutational profile
also displayed low levels of B2M (Fig.9b, c). Com-
parison of EVOLVING and STABLE CRC models
pinpointed other genes differentially expressed in-
cluding CPNE1, IRF1, and PMSB10. These genes are
also involved in immune-related processes and their
downregulation might similarly reduce immune
surveillance of EVOLVING CRCs (Fig. 9a and Add-
itional file 1: Figure S14). We next performed the
analysis showed in Fig. 9a in a multivariate fashion
Fig. 6 Lost and gained mutations across the indicated PDX generations. The color code defines allelic frequencies of acquired SNVs at
each generation (with allelic frequency > 1). The y-axis lists all SNVs identified in each branch; the mouse generation (genealogy) is
reported on the x-axis
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taking into account the growth rates of the cells or
the number of mutations normalized to the doubling
time. The number of statistically significant genes in
the multivariate analyses (Additional file 1: Figure
S15) was lower but consistent with the findings of
Fig. 9a. In the future, it would be interesting to as-
sess whether the differential expression of genes in
fast evolving CRC models has a functional impact.
This aspect cannot be causally predicted at this
stage.
Discussion
In the past decade, it has become clear that most human
tumors are highly molecularly heterogeneous, and this
affects prognosis and the emergence of therapeutic
resistance [40]. How tumor-specific somatic variations can
lead to distinct neoantigen profiles and ultimately to
immune surveillance has also been partially elucidated.
The number of neoantigens depends on several factors.
For example, lung cancers associated with smoking habits
have high levels of mutations [41, 42], whereas the deve-
lopment of skin melanomas is correlated with UV light-
mediated mutagenicity [43]. Both smoking and UV expo-
sure occur during defined periods and their mutagenicity
is transient, leading to high—but relatively stable—muta-
tional profiles [44, 45]. Another class of tumors with high
mutational burden is characterized not by exposure to
external carcinogens, but rather by the intrinsic inability
of tumor cells to efficiently repair DNA. The latter is due
to epigenetic or genetic alterations in key effectors of
Fig. 7 Analysis of cell ploidy in a panel of 64 CRC cell lines. Heatmap showing distribution of ploidy for every segmented region in each
cell line. Samples are sorted from most to less mutated as reported in Fig. 1. The percentage (ploidy) is calculated as described in detail
in the “Methods” section
Table 4 Molecular characterization of patient-derived xenografts
Sample MSI status BRAF KRAS NRAS MLH1 MSH2 MSH3 MSH6 PMS2 POLE
CRC106 MSI V600E WT WT WT WT WT R577H / p.T1085Tfs7* WT WT
CRC542 MSS WT WT WT WT WT WT WT WT WT
CRC371 MSS WT WT E132K R265C WT WT E946* WT V411 L
*Only non-synonymous variants present in COSMIC database are reported
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DNA repair pathways, rather than acute or chronic
carcinogen exposure. In this work, we used CRC as a
model system to understand whether and to what extent
alterations of DNA repair pathway components modulate
neoantigen profiles over time in vitro and in vivo. Tumors
carrying alterations affecting DNA repair genes main-
tained their molecular characteristics over time, and in
most instances, the functional consequence of those alter-
ations is continuous and propagated at every generation.
An exception was represented by two POLE mutant CRC
cell lines (HROC69 and HCC2998) which despite having
high mutational burden did not appreciably evolve over
time. The reason(s) for this phenotype is presently un-
clear. Interestingly, these two POLE mutant cells that
evolved poorly over time had less marked mutational sig-
natures, possibly suggesting that, in these models,
polymerase defects may undergo some form of functional
compensation.
The longitudinal analysis of cell and PDX models
highlighted several aspects. For example, MSI- and
POLE-mutated tumors tended to acquire SNV or short
insertions/deletions over time. These alterations can lead
to novel putative neoantigens which potentially trigger
the host immune system. In addition to well-known
DDR genes (MLH1, MSH2, MSH6, PMS2, POLE), our
study indicate that other genes involved in DNA repair
pathway may lead to accumulations of mutations possibly
translating in novel epitopes. EXO1 and MUTYH are two
of such examples. Profiling of these genes in the clinical
setting may help to intercept tumors not classified as un-
stable or with hypermutator phenotype but nevertheless
continuously evolving and accumulating mutations.
a
b
Fig. 8 Transcriptional analysis of CRC cell lines. Differential expression analysis between hypermutated and non-hypermutated cells. a 183 unique
genes differentially expressed between hypermutated (MSI/POLE) versus non-hypermutated CRC cells (MSS). Log2 expression values along with
the mean change in expression are shown. b Pathway analysis of genes differentially expressed between hypermutated versus non-hypermutated
CRC cells using g:Profiler application (see the “Methods” section)
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Our analysis suggests that in parallel to mutation gains,
loss of variants also occurs during cell propagation. Our
data indicate that in hypermutated CRCs, including MSI-
and POLE-mutated models expanded in vitro, these
events are mainly confined to subclones. A limitation of
this study is that longitudinal characterization of lost and
gained mutations in vitro could be influenced by sampling
of cell populations during cell passaging. We also report
that in the propagation of PDXs, possibly due to selection
imposed by the microenvironment, not only subclonal but
also clonal variants emerge de novo over time. Based on
these results, we speculate that in CRC patients with DNA
repair defects metastatic seeding or therapeutic debulking
can lead to the emergence of new subsets of clonal neo-
antigens. This could have implications for the develop-
ment of therapies relying on the presence of clonal
neoantigens, such as ICP, CAR-T, and vaccines.
Both cell lines and PDXs have been widely employed to
test anticancer compounds [46–48]; however, experimental
reproducibility has occasionally been questioned [49, 50].
The molecular evolvability that we find to occur during
serial passaging of cells and PDXs may partly account for
the discrepant results obtained with these models [51–53].
A limitation of the present study is that it examined
the evolution of cell lines and xenografts but cannot
address the impact of the immune system in the evo-
lutionary dynamics due to intrinsic limitations of the
models we used.
Our data indicate that alterations in DNA repair genes
facilitate the acquisition of neoantigens. These novel
putative epitopes can be recognized by the immune
system. Accordingly, we confirm that CRCs with high
number of mutations (hypermutated CRCs) selectively
downregulate components of the neoantigen presen-
tation process, such as B2M, thus restricting the ability of
the host immune system to detect them. Our results
further suggest that non-hypermutated CRCs, that
display fast evolving mutational and antigen profiles,
also show downregulation of components implicated
in neoantigen presentation. The differences in expres-
sion of molecules involved in immune functions we
observed in the CRC models could have originated
a b
c d
Fig. 9 Beta2 microglobulin (B2M) expression is downregulated in EVOLVING-CRC. Transcriptional and protein levels of the B2M gene. a Genes
differentially expressed in EVOLVING-CRC relative to STABLE-CRC with a significant p value (p < 0.05). b Waterfall chart showing B2M expression at
RNA level across a panel of 45 CRC cell lines. c Western blot analysis of B2M expression. In gray are highlighted samples for which T90
sequencing were not available. Blots were reprobed with anti-HSP90 antibody to confirm equal loading. d B2M gene alterations on 64 CRC cell lines at
T0 (upper panel) and codon affected (lower panel)
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Table 5 List of genes differentially expressed in the indicated
cell lines
gene_id Log2 fold change p adj.
MSS vs MSI
ABCB6 − 1.12 0.01
ACAD11 1.18 0.00
ACOT8 − 1.04 0.00
AHCYL2 1.12 0.02
ALDH6A1 1.34 0.00
AMACR − 1.54 0.01
AOC1 − 1.57 0.04
APBB3 1.04 0.00
ARHGAP18 − 1.01 0.02
ATOX1 − 1.00 0.01
ATP5E − 1.22 0.00
ATP9A − 1.77 0.00
B2M − 1.58 0.00
B4GALT5 − 1.14 0.00
BCL2L15 − 1.73 0.01
BCL9L − 1.09 0.02
BPTFP1 1.09 0.03
C15orf52 − 1.28 0.05
C20orf24 − 1.14 0.00
C6orf48 1.05 0.01
CAPG − 1.30 0.02
CCDC71L − 1.08 0.02
CCND3 − 1.26 0.00
CCPG1 1.16 0.02
CD59 − 1.01 0.03
CD82 − 1.37 0.03
CDKN2A − 3.20 0.00
CEACAM1 − 1.89 0.00
CEACAM6 − 1.71 0.05
CGN − 1.06 0.02
CHKA − 1.13 0.00
CHMP4B − 1.16 0.00
CLDN1 − 1.37 0.05
CLDN3 − 1.58 0.01
COL17A1 − 1.61 0.03
COTL1 − 1.61 0.00
CPNE1 − 1.05 0.00
CPT1B 1.13 0.00
CTSA − 1.10 0.00
CTSD − 1.02 0.03
CTSH − 1.22 0.03
CTSS − 2.46 0.00
CTSV − 1.81 0.00
CTSZ − 1.08 0.01
CUEDC1 − 1.33 0.02
CXXC5 − 1.24 0.01
CYB5D1 1.24 0.00
Table 5 List of genes differentially expressed in the indicated
cell lines (Continued)
gene_id Log2 fold change p adj.
CYFIP2 1.37 0.03
DAB2IP − 1.14 0.00
DCBLD2 − 2.43 0.00
DDX27 − 1.02 0.00
DNTTIP1 − 1.25 0.00
DPEP1 − 1.88 0.04
DYNLRB1 − 1.04 0.00
EDN1 − 1.79 0.01
EMP1 − 1.47 0.03
EPB41L1 − 1.09 0.01
EPB41L4A-AS1 1.04 0.01
EPS8L1 − 1.13 0.03
FCGRT − 1.69 0.00
FECH 1.07 0.00
FKBP1A − 1.02 0.01
FZD7 − 1.02 0.03
GABBR1 1.70 0.01
GABRE − 1.83 0.00
GCAT 1.39 0.00
GLS2 1.38 0.00
GNE − 1.13 0.04
GSN − 1.30 0.03
HELZ2 − 1.14 0.01
HIST1H2AC − 1.36 0.01
HIST1H2BD − 1.92 0.00
HIST1H2BK − 1.48 0.00
HIST2H2AA3 − 1.13 0.03
HIST2H4A − 2.11 0.00
HSPA1A − 1.83 0.02
HSPB1 − 1.41 0.03
HSPH1 − 1.43 0.00
IDH2 − 1.01 0.04
IDS − 1.30 0.02
IFI6 − 1.76 0.03
IRF1 − 1.02 0.01
KRT20 − 1.73 0.04
KRT23 − 4.08 0.00
LAMC2 − 1.77 0.00
LFNG − 1.19 0.02
LGALS1 − 2.88 0.00
LINC01089 − 1.05 0.01
LIPG 1.38 0.00
LPCAT2 − 1.11 0.01
LRRC75A-AS1 1.01 0.04
LRRC8A − 1.23 0.00
LTBP3 − 1.37 0.01
LY6E − 1.41 0.02
LY75 − 1.60 0.01
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Table 5 List of genes differentially expressed in the indicated
cell lines (Continued)
gene_id Log2 fold change p adj.
MACF1 − 1.23 0.01
MALL − 1.20 0.03
MAP7D1 − 1.03 0.02
MAPRE3 − 1.11 0.02
MDM2 1.37 0.00
MGLL − 1.35 0.01
MIR4435-2HG − 1.09 0.05
MMP14 − 1.53 0.02
MOCOS 1.18 0.01
MORC4 1.15 0.00
MUC20 − 1.64 0.02
MYBL2 − 1.13 0.01
MYL5 1.04 0.01
NABP1 − 1.35 0.01
NDUFC2 − 1.22 0.00
OXR1 − 1.12 0.01
PDP1 − 1.01 0.03
PEA15 − 1.29 0.00
PFDN4 − 1.04 0.00
PIGT − 1.00 0.00
PLA2G6 1.17 0.00
PLS3 − 1.21 0.03
PMEPA1 − 2.81 0.00
PML − 1.04 0.00
POLE4 − 1.01 0.01
PPM1M 1.46 0.00
PPP1R14D − 1.98 0.01
PPP1R18 − 1.27 0.01
PRADC1 − 1.19 0.01
PRAP1 − 1.79 0.04
QPCT − 1.89 0.02
QPRT − 2.16 0.00
REG4 2.81 0.00
ROMO1 − 1.14 0.01
RPL22L1 1.62 0.00
RPL32P29 1.31 0.00
S100A11 − 1.62 0.00
S100A2 − 2.35 0.00
S100A4 − 2.70 0.00
SDC4 − 1.30 0.00
SESN2 1.23 0.01
SGK2 − 1.40 0.04
SLC20A2 − 1.07 0.01
SLC2A1 − 1.22 0.04
SLC39A5 − 1.93 0.02
SLC6A6 − 1.40 0.00
SNHG8 1.01 0.01
SNORA73B 1.12 0.02
Table 5 List of genes differentially expressed in the indicated
cell lines (Continued)
gene_id Log2 fold change p adj.
SPINK1 − 2.25 0.01
STAT1 − 1.06 0.01
SULT2B1 − 1.78 0.01
SUPT4H1 1.22 0.00
SYT7 − 1.82 0.00
TCF7 − 1.03 0.04
TFF1 2.17 0.02
TGFBI − 2.43 0.00
TIMP2 − 2.16 0.01
TM4SF1 − 1.70 0.01
TMEM52 1.08 0.03
TMPRSS4 − 1.35 0.04
TNFSF9 2.01 0.00
TRIM7 1.24 0.05
TSPAN6 − 1.49 0.00
TUBA4A − 1.11 0.00
TUBE1 1.12 0.01
TXNDC9 − 1.04 0.00
UCA1 − 1.79 0.03
UCP2 − 1.38 0.03
UNC13D − 1.81 0.01
VAMP8 − 1.09 0.00
VOPP1 − 1.13 0.01
ZMYND8 − 1.11 0.00
ZNFX1 − 1.08 0.00
Hypermutated vs non-hypermutated
ABHD12 − 1.10 0.00
ACOT8 − 1.09 0.00
AHCYL2 1.00 0.01
AKR1C3 − 1.52 0.02
ALDH6A1 1.30 0.00
AMN 1.06 0.04
ANXA6 − 1.94 0.00
AOC1 − 1.96 0.00
ARHGEF10 1.15 0.04
ARL4C − 1.56 0.01
ATOX1 − 1.12 0.00
ATP5E − 1.31 0.00
ATP8B1 1.09 0.00
ATP9A − 1.77 0.00
B2M − 1.82 0.00
BCAS4 − 1.06 0.00
BCL2L1 − 1.02 0.00
BNIP3 1.31 0.02
C15orf52 − 1.10 0.04
C20orf24 − 1.21 0.00
C2orf54 − 2.00 0.00
C7orf50 − 1.20 0.00
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Table 5 List of genes differentially expressed in the indicated
cell lines (Continued)
gene_id Log2 fold change p adj.
CAPG − 1.02 0.03
CCDC71L − 1.00 0.01
CD59 − 1.13 0.00
CD82 − 1.31 0.01
CDKN2A − 1.43 0.03
CEACAM1 − 1.42 0.00
CFD 1.65 0.00
CHKA − 1.17 0.00
CHMP4B − 1.25 0.00
CLDN3 − 1.45 0.00
COL17A1 − 1.33 0.03
COTL1 − 1.67 0.00
CPNE1 − 1.09 0.00
CST3 − 1.29 0.00
CTSA − 1.01 0.00
CTSD − 1.27 0.00
CTSH − 1.31 0.00
CTSS − 2.26 0.00
CTSV − 2.11 0.00
CTSZ − 1.05 0.00
CUEDC1 − 1.59 0.00
CXXC5 − 1.01 0.01
CYB5D1 1.17 0.00
CYTOR − 1.42 0.00
DBNDD2 − 1.06 0.00
DCBLD2 − 2.20 0.00
DGAT2 − 1.04 0.01
DHRS3 − 1.09 0.01
DNTTIP1 − 1.23 0.00
DYNLRB1 − 1.25 0.00
EDN1 − 1.27 0.03
EHD1 − 1.01 0.00
EMP1 − 1.60 0.00
EPB41L1 − 1.06 0.00
EPS8L1 − 1.20 0.00
FAH − 1.28 0.00
FAM84B − 1.10 0.02
FCGRT − 1.60 0.00
FECH 1.27 0.00
FKBP10 − 1.41 0.04
FKBP1A − 1.16 0.00
FUNDC2 − 1.04 0.00
FUNDC2P1 − 1.08 0.00
FZD7 − 1.19 0.00
GABARAPL1 − 1.35 0.01
GABRE − 1.53 0.00
GCAT 1.01 0.01
GNE − 1.03 0.02
Table 5 List of genes differentially expressed in the indicated
cell lines (Continued)
gene_id Log2 fold change p adj.
GPC1 − 1.01 0.05
GSN − 1.75 0.00
HELZ2 − 1.02 0.01
HIST1H2BD − 1.04 0.01
HIST2H4A − 1.38 0.00
HSD11B2 − 1.11 0.03
HSPB1 − 1.20 0.02
IDS − 1.60 0.00
IFI27 − 1.48 0.03
IFI27L2 − 1.03 0.03
IFI6 − 1.86 0.00
IGFBP4 − 1.15 0.02
IL33 1.58 0.04
IRF1 − 1.28 0.00
ISG15 − 1.13 0.04
ITGA3 − 1.23 0.01
ITGB5 − 1.09 0.00
KIFC3 − 1.20 0.04
KLK6 − 2.00 0.00
KRT20 − 1.56 0.02
KRT23 − 3.88 0.00
KRT80 − 1.58 0.00
LAMC2 − 1.57 0.00
LFNG − 1.23 0.00
LGALS1 − 2.44 0.00
LIPG 1.38 0.00
LITAF − 1.20 0.01
LTBP3 − 1.63 0.00
LTBP4 1.17 0.00
LY6E − 1.74 0.00
LY6G6D − 2.03 0.01
LY75 − 1.60 0.00
MAPRE3 − 1.23 0.00
MBOAT2 − 1.03 0.02
MCRIP1 − 1.02 0.00
MDK − 1.36 0.01
MDM2 1.09 0.00
MELTF − 1.18 0.01
MGLL − 1.20 0.00
MIR4435-2HG − 1.47 0.00
MMP14 − 1.64 0.00
MOCOS 1.13 0.00
MOSPD1 − 1.01 0.00
MUC20 − 1.58 0.00
MYBL2 − 1.06 0.00
NABP1 − 1.05 0.01
NDUFC2 − 1.11 0.00
PDP1 − 1.16 0.00
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Table 5 List of genes differentially expressed in the indicated
cell lines (Continued)
gene_id Log2 fold change p adj.
PEA15 − 1.30 0.00
PFDN4 − 1.20 0.00
PHLDB1 − 1.05 0.05
PLAUR − 1.18 0.00
PLTP − 1.53 0.03
PMEPA1 − 2.92 0.00
PML − 1.03 0.00
POLD4 − 1.06 0.00
PPP1R14D − 2.05 0.00
PRDX5 − 1.09 0.00
PRR15 − 1.06 0.03
PRSS23 − 1.09 0.02
PSMA7 − 1.00 0.00
PSMB10 − 1.27 0.00
QPCT − 2.23 0.00
QPRT − 1.32 0.05
RASL11A − 1.19 0.04
REG4 2.99 0.00
RGCC − 2.97 0.00
RGMB 1.49 0.00
RHOD − 1.22 0.01
ROMO1 − 1.28 0.00
RPL22L1 1.12 0.01
RTFDC1 − 1.04 0.00
S100A11 − 1.65 0.00
S100A2 − 2.87 0.00
S100A4 − 1.55 0.02
SDC4 − 1.30 0.00
SLC20A2 − 1.01 0.00
SLC2A1 − 1.42 0.00
SLC2A4RG − 1.04 0.00
SLC2A8 − 1.04 0.00
SLC39A5 − 1.70 0.01
SLCO1B3 1.46 0.05
SMAD3 − 1.08 0.00
SMIM22 − 1.19 0.01
SNORA73B 1.00 0.01
SPINK1 − 2.72 0.00
SULT2B1 − 1.60 0.00
SYT7 − 1.55 0.00
TACSTD2 − 2.32 0.00
TCF7 − 1.18 0.00
TGFBI − 2.28 0.00
TIMP2 − 2.59 0.00
TM4SF1 − 1.78 0.00
TMEM176A − 2.16 0.00
TMEM176B − 1.85 0.01
TMEM185A − 1.07 0.00
Table 5 List of genes differentially expressed in the indicated
cell lines (Continued)
gene_id Log2 fold change p adj.
TMPRSS4 − 1.35 0.01
TNFRSF14-AS1 1.19 0.02
TNFRSF1B − 1.44 0.00
TRIB1 − 1.11 0.02
TRIM7 1.08 0.04
TSC22D1 − 1.01 0.01
TUBA4A − 1.01 0.00
TUBB2A − 1.49 0.00
TUBE1 1.12 0.00
UCA1 − 1.49 0.03
UCP2 − 1.16 0.02
VAMP8 − 1.10 0.00
VEGFB − 1.25 0.00
VOPP1 − 1.27 0.00
VSIR − 1.68 0.00
ZFP90 1.13 0.00
ZMYND8 − 1.07 0.00
EVOLVING-CRC vs STABLE-CRC
ABCB6 − 1.00 0.04
AHI1 1.04 0.02
ANXA6 − 1.83 0.02
ATOX1 − 1.07 0.01
B2M − 1.57 0.00
CPNE1 − 1.12 0.00
FAT1 1.09 0.04
GTF3A − 1.09 0.03
IGFBP6 − 2.01 0.02
IRF1 − 1.05 0.02
LGALS1 − 2.45 0.00
LY6E − 1.47 0.02
PAM − 1.27 0.03
PEA15 − 1.12 0.01
PLA2G2A 2.56 0.01
PSMB10 − 1.05 0.02
S100A2 − 1.96 0.00
SDC4 − 1.04 0.05
SLC7A11 1.63 0.01
TGFBI − 1.50 0.04
TIMP2 − 1.82 0.03
TUBA1A − 1.71 0.05
TUBB2A − 1.55 0.03
TUBE1 1.27 0.01
VEGFA 1.08 0.05
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from adaption previously experienced in the patient
as a mechanism of escape from negative pressure of
the immune system related to the elevated neoanti-
gens’ production rate.
Conclusions
In summary, we identified and functionally highlighted
CRC subsets characterized by slow and fast genome
evolvability. CRCs carrying alterations in genes involved
in DNA repair (including MLH1, MSH2, MSH6, MUTYH,
EXO1, and POLE) display dynamic neoantigen patterns
that fluctuate over time. Furthermore, we find that in
CRC cells and patient-derived tumor xenografts, DNA
repair defects leading to high mutational burden and
neoantigen evolvability are associated with inactivation
or downregulation of antigen-presentation functions.
Longitudinal monitoring of the neoantigen landscape of
CRC and other tumor types may have clinical implica-
tions. While tracking time-dependent neoantigen evo-
lution in the tissue of cancer patients might be difficult
or impossible to achieve, monitoring predicted neoanti-
gens in circulating tumor DNA is already within
reach. Accordingly, longitudinal liquid biopsies could be
deployed to assess whether and how time and/or thera-
peutic regimens affect the mutational burden and the
neoantigen profiles in individual patients. Neoantigen
clonality profiles could be valuable to develop specific
vaccines and deploy immunomodulatory molecules in
the context of precision oncology.
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